Amoebic colitisA06.0

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Amoeba dysentery; invasive intestinal amebiasis

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Intestinal infection with the protozoon Entamoeba histolytica.

ClassificationThis section has been translated automatically.

Entamoeba histolytica.

Occurrence/EpidemiologyThis section has been translated automatically.

  • Worldwide prevalence: about 50 million people worldwide contract invasive amoebiasis annually, up to 100,000 deaths annually (WHO, 1997).
  • Occurrence: mainly in warm countries with low hygienic standards, autochthonous infections in temperate zones very rare (e.g. sewage workers), occurrence in male homosexuals (oral-anal contact, rectal lavage).

EtiopathogenesisThis section has been translated automatically.

Faecal-oral uptake of cysts with contaminated food; release of smaller, vegetative forms, so-called minuta forms (trophozoites) from cysts in the intestine. Trophozoites multiply by bifurcation and form cysts which are excreted with the stool in a mature, quadrenuclear state. When trophozoites penetrate the intestinal wall and phagocytise erythrocytes, they become so-called magnaforms.

Clinical featuresThis section has been translated automatically.

  • Colon: after invasion of trophozoites into the mucosa, undermined ulcerations, so-called bottleneck or canteen ulcers, develop that reach down to the submucosa.
  • Abdominal pain, fever, "raspberry-jelly", slimy-bloody diarrhoea, milder forms: mushy-watery diarrhoea (more frequent), ulcers reaching the submucosa (so-called bottleneck or canteen ulcers), gradual development over several weeks to years. Chronic courses are possible.
  • Perforation
  • Toxic Megacolon
  • Amoeboma.

DiagnosisThis section has been translated automatically.

  • In the chair:
    • Stool culture (to exclude simultaneous bacterial infections)
    • Stool microscopy (sensitivity of 70%): MIFC method in stool (preferably in native stool, fresh stool/mucus flake [in 3 stool samples]): Microscopic detection of cysts, minota forms and magnaforms in stool. Pathogenic and apathogenic forms of intestinal lumen cannot be differentiated, characteristics of cysts: E. histolytica larger than 10 µm, E. histolytica maximum 4 nuclei. Detection of magnaforms is proven by amoebic colitis.
    • Antigen detection (ELISA, sensitivity comparable with microscopy)
    • PCR (highest sensitivity)
  • In serum (indication of invasion):
    • Serum antibodies (ELISA)
    • Transaminases, cholestasis parameters
    • Inflammation parameters
    • Blood count
    • Electrolytes.
  • Imaging (abscess, perforation, toxic megacolon):
    • Abdominal sonography
    • Computer tomography
    • Colonoscopy.

Differential diagnosisThis section has been translated automatically.

  • Diseases that may be associated with similar clinic:
    • Diarrhoea induced by bacterial toxins
    • Shigellose
    • Salmonellosis
    • Campylobacter infection
    • Yersiniosis
    • Chronic inflammatory intestinal diseases
    • Malignant tumors.

Complication(s)This section has been translated automatically.

  • Perforation with peritonitis
  • Toxic megacolon
  • Amoeboma.

TherapyThis section has been translated automatically.

  • Standard: Metronidazole 3 times/day 10 mg/kg bw (max. 3 times/day 800 mg) i.v. or orally over 10 days (dosage for adults and children).
  • In mild cases: Tinidazole 2 g/day orally for 5 days (children: 30 mg/kg bw/day, maximum 2 g/day). Tinidazole is no longer approved in Germany, but is available from pharmacies abroad ( off-label use).
  • Subsequently cyst treatment: Paromomycin 3 times/day 500 mg/day p.o. for 9-10 days (children: 10 mg/kg bw/day).
  • Alternatively: Diloxanidfuroat, Nimorazol, Chloroquin.
  • In pregnant women: treatment indicated (however, 5-nitroimidazole should not be given in the 1st trimester).

ProphylaxisThis section has been translated automatically.

  • Food hygiene (ice cubes, salads, ice cream, open juices)
  • Avoid oral-anal sexual contacts and rectal lavage.

AftercareThis section has been translated automatically.

  • Control of the success of therapy: in severe cases: blood count, liver values, cholestasis and inflammation parameters during and after treatment, time intervals according to the severity of the disease.
  • Stool examination: 6 weeks after the end of treatment.

Note(s)This section has been translated automatically.

Current therapy recommendations can be found in the AWMF guidelines.

LiteratureThis section has been translated automatically.

  1. Annesley J (1828) Researches into the causes, nature and treatment of the more prevalent diseases of warm climates generally. Longman, Rees, Orme, Brown and Green, London, Vol. 2 p. 247
  2. Budd G (1857) On diseases of the liver. Churchill, London, United Kingdom
  3. Burchard GD et al (2003) Therapy of tropical diseases after returning from travel. Internist 44: 633-642
  4. Kucik CJ et al (2004) Common intestinal parasites. On Fam Physician 69: 1161-1168
  5. Losch FA (1975) Massive development of amebas in the large intestine. Translation from the original in Russian. Am J Trop Med Hyg 24: 383-392

Authors

Last updated on: 29.10.2020